Diatrizoate meglumine

Cystografin, Diatrizoate Diatrizoate, Gastrografin, Hypaque, Md, Md-gastroview, Sinografin, Urovist (diatrizoate meglumine) is a small molecule pharmaceutical. Diatrizoate meglumine was first approved as Hypaque on 1982-01-01.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

No data

Trade Name

FDA

EMA

Cystografin (discontinued: Angiovist, Cardiografin, Cystografin, Hypaque, Urovist cysto, Urovist meglumine diu/ct)

Combinations

Diatrizoate meglumine diatrizoate, Gastrografin, Md-gastroview (discontinued: Angiovist, Diatrizoate, Gastrovist, Hypaque, Md, Md-76r, Renocal, Sinografin)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Diatrizoate meglumine

Diatrizoate sodium

Tradename	Company	Number	Date	Products
GASTROGRAFIN	Bracco Diagnostics	N-011245 RX	1982-01-01	1 products, RLD, RS

Show 7 discontinued

Diatrizoate meglumine

Tradename	Company	Number	Date	Products
CYSTOGRAFIN	Bracco Diagnostics	N-010040 RX	1982-01-01	1 products, RLD
CYSTOGRAFIN DILUTE	Bracco Diagnostics	N-010040 RX	1982-11-09	1 products, RLD

Show 7 discontinued

Diatrizoate meglumine

Iodipamide meglumine

Tradename	Company	Number	Date	Products
SINOGRAFIN	Bracco Diagnostics	N-011324 DISCN	1982-01-01	1 products, RLD

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
cystografin	New Drug Application	2018-04-15
cystografin dilute	New Drug Application	2018-10-02
diatrizoate meglumine and diatrizoate sodium	ANDA	2025-02-19
gastrografin	New Drug Application	2021-10-04
hypaque		2006-04-13
hypaque - cysto		2007-08-03
hypaque sodium		2007-08-03
md gastroview	ANDA	2021-01-01
md-gastroview	ANDA	2014-09-29

Indications

FDA

EMA

No data

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

No data

HCPCS

No data

Clinical

Clinical Trials

43 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	—	—	—	1	—	1

Indications Phases 3

No data

Indications Phases 2

No data

Indications Phases 1

No data

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Diatrizoate meglumine
INN	sodium amidotrizoate
Description	Amidotrizoic acid is a member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography. It has a role as a radioopaque medium, an environmental contaminant and a xenobiotic. It is an organoiodine compound, a member of benzoic acids and a member of acetamides. It is a conjugate acid of an amidotrizoic acid anion.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO